ALKS (Alkermes) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Alkermes 3-Year Dividend Growth Rate?

Alkermes's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The historical rank and industry rank for Alkermes's 3-Year Dividend Growth Rate or its related term are showing as below:

ALKS's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 11.1
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Alkermes's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Alkermes's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Alkermes's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkermes's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Alkermes's 3-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

Alkermes 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Alkermes (NAS:ALKS) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Alkermes's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	1.04
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes 3-Year Dividend Growth Rate Related Terms>

Alkermes Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

8AK:Germany 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Executives

Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451